An Open-label Single Oral Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-0518 1200 mg (600 mg Tablet × 2) in Healthy Japanese Male Participants
Phase of Trial: Phase IV
Latest Information Update: 12 Nov 2018
At a glance
- Drugs Raltegravir (Primary)
- Indications HIV infections
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 31 Oct 2018 Status changed from active, no longer recruiting to completed.
- 04 Oct 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 18 Sep 2018 New trial record